Prof Peter Croucher
Principal Research Fellow
Professor Peter Croucher graduated with a BSc in Zoology from University College Cardiff in 1987 and completed a PhD at the University of Wales, College of Medicine, Cardiff, in 1990. Peter’s postdoctoral training was in the Department of Medicine at the University of Cambridge and in the Department of Human Metabolism and Clinical Biochemistry, University of Sheffield. In 1997, Peter was awarded a prestigious five-year Bennett Senior Fellowship by the Leukaemia Research Fund.
He relocated to the University of Oxford, Institute of Musculoskeletal Sciences as a Senior Research Fellow in 2001 and then returned to the School of Medicine and Biomedical Sciences at the University of Sheffield in 2003 as Professor of Bone Biology. In 2009 he was appointed Head of the Department of Human Metabolism and Director of the Mellanby Centre for Bone Research. In 2011, Peter moved to the Garvan Institute of Medical Research where he is now Head of the Division of Bone Biology.
In the NewsKnow Your Bones: new online bone health assessment tool launches - Jun 16, 2016
How to wake a sleeping cancer cell – and why you might want to - Dec 04, 2015
Garvan gets behind Movember - Nov 05, 2015
Scott Youlten Wins 2015 UNSW Faculty of Medicine Three Minute Thesis Competition - Jul 07, 2015
Garvan led team wins prestigious prostate cancer award - Mar 13, 2014
Knockout finding reveals large number of genes that affect our bones - Aug 03, 2012
1987 - BSc (Hons) Zoology, University College Cardiff - UK
Croucher PI, McDonald MM, Martin TJ. Bone metastasis: the importance of the neighbourhood. (2016) Nat Rev Cancer. May 25;16(6):373-86.
Lawson MA, McDonald MM, Kovacic N, Hua Khoo W, Terry RL, Down J, Kaplan W, Paton-Hough J, Fellows C, Pettitt JA, Neil Dear T, Van Valckenborgh E, Baldock PA, Rogers MJ, Eaton CL, Vanderkerken K, Pettit AR, Quinn JM, Zannettino AC, Phan TG, Croucher PI. Osteoclasts control reactivation of dormant myeloma cells by remodelling the endosteal niche. (2015) Nat Commun. Dec 3;6:8983.
Croucher PI, Parker BS, Corcoran N, Rogers MJ. Bone Turnover Markers and Prostate Cancer: Not Just a Measure of Bone Disease? (2015) Eur Urol. Jul;68(1):51-2.
Bassett, J.H.D., Gogakos, A., White, J.K., Evans, H., Jacques, R.M., Van der Spek, A., Sanger Mouse Genetics Project, Ramirez-Solis, R., Ryder, E., Sunter, D., Boyde, A., Campbell, M.J., Croucher, P.I., Williams, G.R. (2012) Rapid-throughput skeletal phenotyping of 100 knockout mice identifies 9 new genes that determine bone strength. PLoS Genetics. 8:e1002858.
Baud’huin, M., Nicolas Solban, N., Cornwall-Brady, M., Sako, D., Kawamoto, Y., Liharska, K., Lath, D., Bouxsein, M.L., Underwood, K.W., Ucran, J., Kumar, R., Pobre, E.G., Grinberg, A.V., Seehra, J., Canalis, E., Pearsall, R.S., Croucher, P.I. (2012) A Soluble Alk3/BMPR1A Receptor Increases Bone Mass and Bone Strength. Proceedings of the National Academy of Sciences USA. 109:12207-12212.
Vitovski, S., Chantry, A.D., Lawson, M.A., Croucher, P.I. (2012) Targeting tumour-initiating cells with TRAIL based combination therapy ensures complete and lasting eradication of multiple myeloma tumours in vivo. PloS One, 7(5):e35830.
Chantry, A.D., Heath, D., Mulivor, A., Pearsall, R.S., Baud’huin, M., Coulton, L., Evans, H., Abdul, N., Werner, E.D., Bouxsein,M.L., Key, M.L., Arnett, T.R., Seehra, J., Vanderkerken, K., Croucher, P.I. (2010) Inhibiting activin-A signaling stimulates bone formation and prevents cancer induced bone destruction in vivo. Journal of Bone and Mineral Research. 25:2357-2370.
Heath, D.J., Chantry, A.D., Buckle, C., Coulton, L., Shaughnessy Jr, J.D., Evans, H., Stover, D.R., Vanderkerken, K., Croucher, P.I. (2009) Inhibiting Dickkopf-1 (Dkk-1) prevents the development of osteolytic bone disease in multiple myeloma. Journal of Bone and Mineral Research, 24:425-436.
Heath, D.J., Vanderkerken, K., Cheng, X., Gallagher, O, Prideaux, M., Murali, R., Croucher, P.I. (2007). An Osteoprotegerin-like peptidomimetic inhibits osteoclastic bone resorption and osteolytic bone disease in myeloma. Cancer Research, 67:202-208.
Vitovski, S., Phillips, JS, Sayers, J, Croucher, P.I. (2007). Investigating the interaction between osteoprotegerin and receptor activator of NF-kappaB or tumor necrosis factor-related apoptosis-inducing ligand: evidence for a pivotal role for osteoprotegerin in regulating two distinct pathways. Journal of Biological Chemistry, 282:31601-31609.
Vanderkerken, K., Medicherla, S., Coulton, L., De Raeve, H., Willems, A., Lawson, M., Van Camp, B., Protter, A.A., Higgins, L.S., Menu, E., Croucher, P.I. (2007). Inhibition of p38alpha mitogen-activated protein kinase prevents the development of osteolytic bone disease, reduces tumor burden, and increases survival in murine models of multiple myeloma. Cancer Research, 67:4572-4577.
Edwards, C.M., Mueller, G., Roelofs, A Chantry, A., Perry, M., Russell, R.G.G., Van Camp, B, Guyon-Gellin, Y, Niesor, E, Bentzen, C., Vanderkerken, K., Croucher, P.I. (2007). Apomine, an inhibitor of HMG-CoA-reductase, promotes apoptosis of myeloma cells in vitro and is associated with a modulation of myeloma in vivo. International Journal of Cancer, 15:1657-1663.
Karadag, A., Zhou, M., Croucher, P.I. (2006) ADAM-9 (MDC-9/meltrin-g), A Member of the A Disintegrin and Metalloproteinase Family, Regulates Myeloma Cell Induced Interleukin-6 Production in Osteoblasts by Direct Interaction with the avb5-Integrin. Blood, 107:3271-3278.
Croucher, P.I., De Raeve, H., Perry, M.J., Hijzen, A., Shipman, C.M., Lippitt, J., Green, J., Van Marck, E., Van Camp, B., Vanderkerken, K. (2003) Zoledronic acid prevents the development of osteolytic bone lesions and increases survival in the 5T2MM murine model of multiple myeloma. Journal of Bone and Mineral Research. 18:482-492.
Shipman, C.M., Croucher, P.I. (2003) Osteoprotegerin is a soluble decoy receptor for TRAIL/Apo2L and can inhibit TRAIL/Apo2L-induced apoptosis of human myeloma cells in vitro. Cancer Research. 63:912-916.
Vanderkerken, K., De Leenheer, E., Shipman, C.M., Asosingh, K., Willems, A., Van Camp, B., Croucher, P.I. (2003) Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma. Cancer Research. 63:287-289.
Holen, I., Croucher, P.I., Hamdy, F., Eaton, C.L. (2002) Osteoprotegerin (OPG) is a survival factor for human prostate cancer. Cancer Research, 62:1619-1623.
Croucher, P.I., Shipman, C.M., Lippitt, J., Perry, M., Asosingh, K., Hijzen, A., Brabbs, A.C., van Beek, E.J.R., Holen, I., Skerry, T.M., Dunstan, C.R., Russell, R.G.G. Russell, Van Camp, B., Vanderkerken, K. (2001) Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. Blood, 98:3534-3540.